Dermata Therapeutics Inc
DRMAW0.020USD
-0.005-21.88%
Cierre 04/24, 16:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Información de Dermata Therapeutics Inc Compañía
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Información de la empresa
Código de la empresaDRMAW
Nombre de la empresaDermata Therapeutics Inc
Fecha de salida a bolsaAug 13, 2021
Fundada en2014
Director ejecutivoMr. Gerald T. (Gerry) Proehl
Número de empleados- -
Tipo de títulosCompany Warrant
Fin del año fiscal- -
Dirección3525 Del Mar Heights Rd., #322
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal92130
Teléfono18582230882
Sitio Webhttps://www.dermatarx.com/
Código de la empresaDRMAW
Fecha de salida a bolsaAug 13, 2021
Fundada en2014
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
--
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
--
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
Dr. Maria Bedoya Toro Munera, Ph.D.
Dr. Maria Bedoya Toro Munera, Ph.D.
Senior Vice President - Regulatory Affairs & Quality Assurance
Senior Vice President - Regulatory Affairs & Quality Assurance
--
--
Ms. Mary M. Fisher
Ms. Mary M. Fisher
Independent Director
Independent Director
--
--
Dr. Andrew S. Sandler, M.D.
Dr. Andrew S. Sandler, M.D.
Independent Director
Independent Director
--
--
Ms. Brittany K. Bradrick
Ms. Brittany K. Bradrick
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Ms. Kyri K. Van Hoose
Ms. Kyri K. Van Hoose
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Independent Director
Independent Director
--
--
Dr. Christopher J. Nardo, Ph.D.
Dr. Christopher J. Nardo, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
--
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David F. Hale
Mr. David F. Hale
Lead Independent Director
Lead Independent Director
--
--
Dr. Steven J. Mento, Ph.D.
Dr. Steven J. Mento, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
No datos encontrados
No datos encontrados
Por negocio
Por región
No datos encontrados
Accionista
Hora de actualización: dom., 23 de feb
Hora de actualización: dom., 23 de feb
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Other
100.00%
Estadísticas de accionistas
Accionista
Proporción
Other
100.00%
Tipo
Accionista
Proporción
Other
100.00%
Participación institucional
Hora de actualización: lun., 3 de mar
Hora de actualización: lun., 3 de mar
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
6
30.45K
0.00%
-15.89K
2024Q4
6
30.45K
0.00%
-15.89K
2024Q3
5
16.34K
0.00%
-51.21K
2024Q2
6
222.24K
0.00%
-16.66K
2024Q1
6
238.90K
0.00%
-306.46K
2023Q4
6
545.35K
0.00%
+302.33K
2023Q3
6
242.92K
0.00%
+5.51K
2023Q2
6
237.31K
0.00%
-9.97K
2023Q1
6
247.28K
0.00%
-332.43K
2022Q4
6
579.72K
0.00%
-41.18K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Two Sigma Investments, LP
12.86K
0%
+12.86K
--
Dec 31, 2024
Boothbay Fund Management, LLC
12.00K
0%
--
--
Dec 31, 2024
UBS Financial Services, Inc.
4.14K
0%
-100.00
-2.36%
Dec 31, 2024
Armistice Capital LLC
1.35K
0%
+1.35K
--
Dec 31, 2024
BofA Global Research (US)
100.00
0%
--
--
Dec 31, 2024
Warberg Asset Management LLC
--
0%
-30.00K
-100.00%
Sep 30, 2024
ETF relacionados
Nombre
Proporción
No datos encontrados
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados